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Valorization
Neurodegenerative diseases, such as Parkinson’s disease (PD) and Huntington’s
disease (HD) are debilitating, progressive disorders that result in a significant
reduction in quality of life and substantial healthcare costs for affected indi-
viduals. PD is the 2nd most common neurodegenerative disease, with a rising
prevalence according to age. In persons between 40-49 years, PD occurs in
41 cases per 100 000. The incidence drastically increases up to 1903 cases
per 100 000 persons over 80 (Pringsheim, Jette et al. 2014). This number
is expected to increase (Dorsey, Constantinescu et al. 2007). HD is a rare
disorder with variable prevalence among geographic locations, but it has a
substantial direct economic burden. In Western Europe, HD has an average
prevalence of 3.6 cases per 100 000 (Squitieri, Griguoli et al. 2015, Rawlins,
Wexler et al. 2016). Individuals who may be at risk for these diseases were
the target group for the first part of this thesis, as we focused on generat-
ing information that can be utilized during genetic counselling for both diseases.
Recently, there has been a drive to identify individuals years before they
develop clinical disease to find a population in which disease-preventing thera-
pies could be tested (Paulsen, Langbehn et al. 2008, Noyce, Mencacci et al.
2014). This has generated an ethical dilemma, especially in HD, as there is
currently nothing that can be done to prevent the onset of disease. However,
the age-of-onset of HD could be delayed by environmental factors like physical
activity, stress levels and diet (Mo, Hannan et al. 2015). Current guidelines for
genetic counselling recommend against using predictions of diagnosis age based
on CAG-repeat expansion length, in part because no curative or preventive
treatments are available, and also because such estimates have large confidence
intervals (Paulsen, Langbehn et al. 2008). The uptake of genetic testing for
HD has remained under 25% of at-risk individuals since genetic testing has
become available (Tassicker, Teltscher et al. 2009).
Identifying other modifiers of the disease onset which can improve the ac-
curacy of disease-onset predictions is crucial to improve the genetic counselling
services available to the HD population and assist the individuals which do
wish to know with their career trajectory and future social support needs
(Baig, Strong et al. 2016). In chapter 4 of this thesis, we identified perinatal
modifiers of the age-of-onset of HD. This has direct applications for counselling
patients with HD. We investigated the disease-free survival of individuals
at-risk for HD which also had a perinatal insult. The inclusion of at-risk
individuals is innovative since the majority of previous age-of-onset studies
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been based only on onset ages for CAG-expanded individuals with manifest
disease, leading to possible bias from ignoring age distributions among those
who have not developed the illness (Paulsen, Langbehn et al. 2008). We
followed the epidemiological observations up with molecular insights of the
effect of perinatal insults on the striatum, which is affected in HD. This was
reviewed in chapter 5. In chapter 6 we showed that perinatal asphyxia (PA)
increases nitrosidative stress in the striatum, which is known to degenerate in
HD. This is a possible molecular mechanism for the accelerated disease onset
seen in HD patients with perinatal insults.
In PD there is the additional ethical dilemma that only 5-10% of cases can
be ascribed to a currently known monogenetic cause (Bekris, Mata et al. 2010).
In the majority of cases, PD is caused by a combination of genetic risk and
environmental factors, which could potentially be modified by lifestyle changes
such as exercise (Ahlskog 2011). Identifying individuals at an increased risk
could potentially facilitate earlier diagnosis and lifestyle changes to prevent
the disease. Mutations in the GBA gene are the most common large-effect
risk factor for PD, conferring a 9.1% chance of developing the disease before
80 years (Alcalay, Dinur et al. 2014). We discussed how GBA mutations
contribute to PD risk in detail in chapter 2. We also highlighted that the
activity of the GBA enzyme can be boosted by chaperones and this has had
promising results in in vitro and animal models (Barkhuizen, Anderson et al.
2016). These chaperones are good candidates for genotype-specific modifier
trials in Parkinson’s disease. In chapter 3, we investigated the prevalence
and mutation spectrum of GBA mutations in South Africans with Parkinson’s
disease. This knowledge improves the genetic counselling options for South
Africans and opens up the possibilities of finding GBA-mutation carriers in
South Africa to include in clinical trials. Since currently, the genetic status
cannot be changed and perinatal insults are still prevalent, despite improve-
ments in maternal care, it is vital to identify therapeutics to limit the damage
after these insults.
Given the importance of perinatal events, we focused on therapeutic strate-
gies for PA in the very low gestational age (VLGA) infant in the remainder
of this thesis. Hypoxic-ischemic encephalopathy (HIE) due to PA is a com-
mon cause of long-term neurological injury in the period around birth. The
prevalence of HIE varied from 160 cases per 100 000 live births in high income
countries to 1490 cases per 100 000 births in Sub-Saharan Africa with an
average global incidence of 850 infants per 100 000 live births globally. This
amounted to 1.15 million neonates in 2010 Africa and South-East Asia (Lee,
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Kozuki et al. 2013). In the same period, there were an estimated 15 million
preterm births, before 37 weeks of gestation, worldwide (Blencowe, Cousens
et al. 2012). Birth before 37 weeks of gestation occurred in approximately
5-8% of all pregnancies. Very low gestational age (VLGA) births, before 32
weeks of gestation, occurred in approximately 1% of singletons and 9% of
twin pregnancies (Schaaf, Mol et al. 2011). With advances in medical care,
a large proportion of these infants can survive up to adulthood and old-age
(Volpe 2009a). The final outcome of encephalopathy due to an asphyxic insult
varies among infants according to the severity and the duration of the insult
and on the physiological and maturational status of the neonate. Preterm
infants are at a greater risk for long-term complications. Motor and cognitive
impairment after perinatal asphyxia results in a considerable economic burden
(Rees, Harding et al. 2011, Eunson 2015).
Although therapeutic cooling is routinely used in term infants with PA
(Davidson, Wassink et al. 2015), it is not yet approved for preterm infants,
and small trials indicate that the risk-benefit ratio of this therapy may be
unfavorable in VLGA infants (Walsh, Butler et al. 2015). Thus, there is an
unmet need for therapies for these infants. In the review in chapter 5, we
assessed the usefulness of a rat model of global PA in the VLGA infant as
a screening tool for therapeutic approaches. We investigated the potential
of mono-target drugs for PA in the VLGA infant on a molecular level. In
chapter 6, we show that therapies which prevent supra-physiological increases
in nitric oxide synthesis could potentially still be given within 1 week after the
insult. This defined a time-window in which to test NO-directed drugs in future
preclinical work. In chapter 7, we investigated the potential of antagonizing
glutamatergic receptors with anesthetics as a mechanism to protect the basal
ganglia.
In chapters 8 and 9, we expanded our investigations to a biological therapy
which have an effect on several molecular processes. We tested the preclinical
efficacy of multipotent adult progenitor cells (MAPCs) in the PA rat model.
Stem cell products have shown therapeutic promise in the ischemia field due
to the restorative properties of these cells. The MAPCs are a commercially
viable cell product, which uses cells with a lower immunogenic phenotype and
higher proliferative potential than the mesenchymal stem cells (MSCs) (Jacobs,
Roobrouck et al. 2013). We provided early biochemical pathways altered by
these cells which partially elude the mechanisms of these cells; and we evaluated
the long-term functional performance of the treated rats to determine which
domains should be monitored in human clinical trials with these cells.
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In conclusion, the research described in this thesis has improved the knowl-
edge on factors which modulate the disease-onset in PD and HD, which could
be utilized by genetic counsellors for these diseases. We have also expanded
the range of therapies which could be developed further for PA in the VLGA
infant. These findings contribute to the race to prevent and cure these disorders
and pave the way for a well-designed clinical trial based on a sound biological
understanding.
